TFF Pharmaceuticals News

Express News | TFF Pharmaceuticals Inc - Mcm Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated in Vitro and Ex Vivo Models

BreakingsMay 23 19:07

Express News | TFF Pharmaceuticals Inc - Co and Leidos to Advance Next-Generation Biodefense Countermeasures Under Darpa PPB Program Into Preclinical Testing

BreakingsMay 23 19:07

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates Into Preclinical Testing

FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing

GlobeNewswireMay 20 19:00

TFF Pharmaceuticals Entered Into An At Market Offering Agreement With H.C. Wainwright & Co., LLC

TFF Pharmaceuticals Entered Into An At Market Offering Agreement With H.C. Wainwright & Co., LLC

BenzingaMay 18 04:19

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TipRanksMay 16 20:25

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety E

GlobeNewswireMay 15 19:00

TFF Pharmaceuticals Expects To Receive FDA Feedback In Q2 Regarding TFF TAC Clinical Development Plan And Next Steps

TFF Pharmaceuticals Expects To Receive FDA Feedback In Q2 Regarding TFF TAC Clinical Development Plan And Next Steps

BenzingaMay 15 04:43

TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate

TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.40) per share which missed the analyst consensus estimate of $(2.26) by 6.19 percent. The company reported quarterly sales of $203.2

BenzingaMay 15 04:42

TFF Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 15 04:08 · Announcements

Press Release: TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC)

Dow JonesMay 15 04:05

TFF Pharmaceuticals 1Q Loss/Shr $2.40 >TFFP

TFF Pharmaceuticals 1Q Loss/Shr $2.40 >TFFP

Dow JonesMay 15 04:05

Press Release: TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering

TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the "Company" or "TFF Pha

Dow JonesMay 2 05:07

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell

TFF Pharmaceuticals (TFFP) said late Monday it priced a public offering of about 1.7 million common shares and warrants to purchase up to about 1.7 million shares at a combined price of $2.875 per sha

MT NewswiresApr 30 17:53

Reported Earlier, TFF Pharmaceuticals Prices $4.8M Public Offering Of 1,665,219 Shares And Warrants At $2.875/Share Accompanying Warrant

TFF Pharmaceuticals announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,66

BenzingaApr 30 16:35

TFF Pharmaceuticals' 1.7 Million-Share Offering Prices at $2.875 a Share >TFFP

TFF Pharmaceuticals' 1.7 Million-Share Offering Prices at $2.875 a Share >TFFP

Dow JonesApr 30 08:00

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and

GlobeNewswireApr 30 08:00

TFF Pharmaceuticals Signals Advancements in Investor Update

TipRanksApr 29 18:22

TFF Pharmaceuticals Announces Additional Data From the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film F

BenzingaApr 15 19:11

TFF Pharmaceuticals Files to Sell Common Stock, Warrants

Seeking AlphaApr 8 19:39

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)

TipRanksApr 5 01:20